Aaron joined Freenome as CEO in April 2025. He previously served as CEO and president of REALM IDx, Inc., for nearly four years, overseeing its subsidiaries Ambry Genetics, Invicro and Konica Minolta REALM-Japan. He led the acquisition of Ambry by Konica Minolta for $1 billion in 2017.
From 2016 to 2021, Aaron led Ambry Genetics as CEO and transformed the company into one of the largest hereditary cancer testing labs in the world. He joined Ambry in 2008 as an R&D scientist and would later become its chief scientific officer. His experience includes the creation and launch of several first-to-market tests and technologies, including the first CLIA/CAP exome test, hereditary cancer panels, and paired RNA and DNA germline tests.
Aaron did his genetics Ph.D. training at the Sidney Kimmel Cancer Center at Thomas Jefferson University and The Johns Hopkins University School of Medicine, and he holds a Bachelor of Science in Biology from Franklin & Marshall College.
LinkedIn
Ann is a seasoned healthcare and life sciences executive with more than 30 years of global leadership experience in diagnostics and medical technology. She most recently served as Head of Roche Diagnostic Solutions and as a member of the Roche Diagnostics Executive Committee. From 2020 to 2023, Ann led Roche Diagnostic Solutions globally, overseeing a business with approximately 6,000 employees and sales of CHF 12.7 billion in 2023.
Previously, she served as Head of the Centralized Diagnostics & Point of Care Business Area and as President of Roche Tissue Diagnostics. Throughout her career at Roche Diagnostics, Ann held a number of senior leadership positions across commercial, operational and strategic functions in both Europe and the United States.
Ann currently serves on the boards of Elekta AB, Senzime AB and IBEX Medical Analytics. She holds a Bachelor's in Biomedical Science from the Dublin Institute of Technology in Ireland.
LinkedIn
Peter is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Peter is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools and serves on the boards of publicly and privately held life science companies. Peter also leads the firm’s engagement and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policymakers, and industry.
Peter served on the Board of Global Science and Technology for the National Academy of Sciences, is the author of The Entrepreneur’s Guide to a Biotech Startup, and frequently writes and speaks on the future of biotechnology innovation. Peter founded and serves as a Director of No Patient Left Behind, a non-profit advocate for healthcare reforms that would make today’s medicines affordable to patients and promote the innovation that gives all of us hope for tomorrow.
Peter holds a bachelor’s degree from Cornell University and a PhD in virology from Harvard University.
LinkedIn
Carole joined the Freenome board in May 2026. In March 2026, she retired as the Head of Roche Venture Fund (RVF), the corporate venture fund of the Roche Group that she had established in 2001. During her tenure at RVF, Carole made over 30 successful investments in diverse companies, including Alios, AveXis, Envoy, Lysosomal Therapeutics Inc, Nimble Therapeutics, and Pharmasset.
Currently, Carole serves on the board of Aligos Therapeutics, Inc, a public biotech company. Previously, she served as a director on the following public boards: AveXis, BCTG Acquisition Corp, Entrada, and Millendo. Before joining Roche, Carole was the general counsel of SangStat, which was later acquired by Genzyme.
Carole holds a bachelor’s degree from Valparaiso University and a Juris Doctorate from the University of Michigan.
LinkedIn
Deepa is currently the CEO of an oncology company operating in stealth mode. Previously, she spent more than two decades as a Managing Member and Senior Partner at Delphi Ventures. Prior to joining Delphi, Deepa was an M&A and corporate finance banker in the healthcare group at J.P. Morgan, and a biotechnology research analyst and postdoctoral scientist in the Immunology Department at Genentech.
Deepa serves on the boards of Palleon Pharmaceuticals, Mereo BioPharma and Karyopharm. She previously served on the boards of Theravance Biopharma, Alder Pharmaceuticals, Alexza Pharmaceuticals and Calithera Biosciences. She received her Ph.D. and Masters in Science from Wake Forest University and her M.Sc. and B.Sc. from the University of Bombay.
LinkedIn
Randy is currently Chair and CEO of Genomic Life, a genetics-based healthcare navigation company. He, is a co-founder of multiple biotech companies, including Incyte (NASDAQ: INCY), a biopharma company; Genomic Health (acquired by Exact Sciences), one of the first cancer precision medicine companies; and Invitae (acquired by Labcorp), one of the largest U.S. genetic testing companies.
Randy is an author of more than 40 scientific publications, holds 20 patents, and is the recipient of numerous awards, including the Ernst & Young 1997 Entrepreneur of the Year Award for Silicon Valley.
Randy holds a Bachelor of Science degree in Chemistry from Emporia State University and a Ph.D. in Biochemistry from the University of Kansas.
LinkedIn
Doug is the former Chairman and Chief Executive Officer of NeoGenomics, Inc., having served in that role for 12 years prior to his retirement in early 2021. Under his leadership, the company grew from $20 million to nearly $500 million in revenue; increased its employee count from 100 to more than 1,800; grew its market capitalization from $25 million to $5+ billion; and became a NASDAQ-listed company.
Previously, Doug was General Partner of a private equity firm and Founding Managing Partner of a venture-capital firm. He previously served in various executive positions at Corning Incorporated and its spin-off company, Quest Diagnostics, Inc.
Doug currently serves as a Trustee for Florida Gulf Coast University, and he is also a member of the Board of Directors of several non-profit organizations. He is Chair of the Florida Gulf Coast University Foundation. In addition, Doug is a founder and co-owner of a privately held chain of 15 retail hardware stores throughout Florida. He is a graduate of Bentley University.
LinkedIn